Clinical trial
Meibomian Gland Probing in the Sub-Acute Phase of Patients With Stevens-Johnson Syndrome/Toxic Epidermal Necrolysis
NCT05145959 is registered in ClinicalTrials.gov with Massachusetts Eye and Ear Infirmary as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- Meibomian Gland Probing in the Sub-Acute Phase of Patients With Stevens-Johnson Syndrome/Toxic Epidermal Necrolysis
- Lead sponsor
- Massachusetts Eye and Ear Infirmary
- Phase
- Not applicable
- Overall status
- Unknown status
- Start date
- December 1, 2021
- Completion date
- March 1, 2024
- Enrollment
- 30 (estimated)
- Sites
- 1
Conditions
As the registry lists them; a condition with its own page is linked.
dry eye, meibomian gland dysfunction, meibomitis, ocular surface disease, stevens-johnson syndrome, toxic epidermal necrolyses